echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Practice-oriented, "move" the road to peers! ASCT Transplantation Scholar Ceremony - ASCT HOW came to a successful conclusion

    Practice-oriented, "move" the road to peers! ASCT Transplantation Scholar Ceremony - ASCT HOW came to a successful conclusion

    • Last Update: 2022-09-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    "Move" the road together, although far will reach! Sponsored by the Hematology and Oncology Committee of the Chinese Anti-Cancer Association (CACA), the Autologous Hematopoietic Stem Cell Transplantation (ASCT) Working Group of the Chinese Society of Clinical Oncology (CSCO), and the National Clinical Medical Center for Hematologic Diseases, and co-organized by Kaixin Yuanda Pharmaceutical (China) Co.



    Professor Qiu Lugui and Professor Zou Dehui of the Hematology Hospital of the Chinese Academy of Medical Sciences served as the executive chair, and invited more than 50 domestic experts in various fields of hematology and tumors to gather online to comprehensively interpret ASCT from multiple myeloma (MM) and the application of ASCT in multiple myeloma (MM) and other plasma cell diseases, lymphoma and leukemia, and shared the clinical experience of ASCT in various centers to discuss the current progress of ASCT exploration and hot issues




    At the beginning of the meeting, Professor Shen Zhixiang of Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Professor Ma Jun of Harbin Institute of Hematology and Oncology, Professor Wang Jianxiang of Hematology Hospital of Chinese Academy of Medical Sciences, Professor Wu Depei of the First Affiliated Hospital of Soochow University, Professor Hu Yu of Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, and Professor Qiu Lugui, Executive Chairman, said in their opening speeches that ASCT is a traditional and classic treatment method for patients with blood tumors




    Under the co-chairing of Professor Zhu Jun and Professor Qiu Lugui of Peking University Cancer Hospital, Professor Qiu Lugui, Professor Zou Dehui, Professor Xie Wenjun of The Blood Disease Hospital of the Chinese Academy of Medical Sciences, Professor Wang Fengrong of Peking University People's Hospital, Professor Yang Guangzhong of Beijing Chaoyang Hospital Affiliated to Capital Medical University, and Professor Cai Zhen of the First Affiliated Hospital of Zhejiang University School of Medicine respectively from the status of transplantation, the mobilization of dry collection before transplantation, the selection of transplant pretreatment protocols, the prevention and treatment of common side effects after transplantation, and the cracking of the problem of transplant warehouse shortage.




    ASCT is one of the most important treatments for patients with hematological tumors, and common applications are MM, lymphoma and leukemia




    In the "Big Coffee Talk" session, Professor Song Yongping of the First Affiliated Hospital of Zhengzhou University, Professor Ji Chunyan of Qilu Medical College of Shandong University, Professor Niu Ting of West China Hospital of Sichuan University, and Professor Mi Jianqing of Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine conducted in-depth exchanges




    Bone keeping the original intention, ASCT reconstructs the new vitality of myeloma patients

    Under the co-chairing of Professor Chen Wenming of Beijing Chaoyang Hospital affiliated to Capital Medical University and Professor Lu Jin of Peking University People's Hospital, Professor An Gang of the Hematology Hospital of the Chinese Academy of Medical Sciences, Professor Li Juan of the First Affiliated Hospital of Sun Yat-sen University, Professor Fu Zhenxuan of the First Affiliated Hospital of Soochow University, Professor Du Juan of Shanghai Changzheng Hospital, and Professor Huang Xianghua of the General Hospital of the Eastern Theater respectively focused on the application of ASCT in MM and other plasma cell diseases.
    Clinical experience
    was shared in various aspects such as disease treatment and management of patients with high-risk and renal damage MM.

    MM is a malignant tumor with abnormal plasma cell proliferation that cannot be cured
    at present.

    In the era of new drugs, MM treatment has made significant progress, but ASCT is still the standard first-line treatment option
    suitable for patients with transplanted MM.

    During clinical treatment, the patient's age, physical condition, organ function, comorbidities and other factors should be comprehensively judged whether it is suitable for transplantation
    .

    For patients suitable for transplantation MM, melphalan 200mg/m2 (Mel200) is its standard pretreatment protocol and has been recommended by several domestic and foreign guidelines
    .

    After transplantation, maintenance therapy can be selected according to its depth of remission, risk stratification and other factors to further strengthen disease control
    .

    In addition, PATIENTS WITH MM ARE often associated with renal impairment, and ASCT is also a safe and effective treatment for these patients, which may not only improve their haematological and renal remission rates, but also successfully remove dialysis patients from dialysis treatment
    .

    In patients with MM with high-risk cytogenetic abnormalities, micro residual disease (MRD) is negative or can overcome its poor prognosis
    with sequential ASCT therapy.

    In patients with systemic light chain amyloidosis (AL) suitable for transplantation, induction therapy may increase deep remission after ASCT, and risk stratification should be optimized to guide treatment
    .

    In the "Big Coffee Talk" session, Professor Fu Weijun of shanghai Fourth People's Hospital affiliated to Tongji University, Professor Wang Luqun of Qilu Hospital of Shandong University, Professor Sun Chunyan of Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, and Professor Li Nainong of Union Hospital Affiliated to Fujian Medical University discussed in depth the first-line treatment strategies suitable for transplanted MM patients, emphasized the importance of MM whole process management, emphasized that MM treatment needs to be aimed at prolonging patient survival and improving patient quality of life, and suggested that patients should be comprehensively considered for risk stratification and physical condition 3.
    The depth of remission and the benefits of ASCT, and ASCT work
    should be carried out in a center with rich transplantation experience.


    Undaunted by lymphatic danger, ASCT draws a new blueprint for lymphoma treatment

    Under the co-chairing of Professor Wang Chun of Shanghai Zhaxin Hospital of Gaobo Medical Group and Professor Li Jianyong of Jiangsu Provincial People's Hospital, Professor Liu Weiping of Peking University Cancer Hospital, Professor Liu Wei of Hematology Hospital of Chinese Academy of Medical Sciences, Professor Jin Zhengming of the First Affiliated Hospital of Soochow University, Professor Fan Lei of Jiangsu Provincial People's Hospital, Professor Zhang Xi of Xinqiao Hospital of Army Military Medical University, and Professor Huang Liang of Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology on the different subtypes and risk stratification of lymphoma.
    From multiple dimensions such as the number of treatment lines and treatment strategies, the insights
    on the application of ASCT are elaborated.

    Lymphoma has a wide variety of subtypes, and different subtypes of patients are more heterogeneous and the treatment is also different, so it is important to know exactly the type of patient to which ASCT is
    applicable.

    Many authoritative guidelines and consensus at home and abroad recommend that ASCT can be used as a standard salvage treatment plan for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and relapsed/refractory peripheral T-cell lymphoma (PTCL); In addition, young, high-risk patients such as DLBCL and somatic lymphoma (MCL) can also benefit
    from first-line ASCT consolidation therapy.

    Because most patients with PTCL have limited efficacy with conventional chemotherapy, first-line consolidation therapy
    with ASCT is recommended after the first complete response (CR1).

    BEAM (carmustine + etoposide + cytarabine + melphalan) scheme is the classic pretreatment scheme for lymphoma patients, due to the shortage of carmustine supply, scholars at home and abroad have carried out a series of alternative solutions to explore, found that GBM (gemcitabine + busulfan + melphalan), SEAM (smustine + etoposide + cytarabine + melphalan) and other optimization schemes can be used as a feasible alternative treatment option
    .

    At present, new drugs are emerging in an endless stream, and new therapies such as ASCT combined with chimeric antigen receptor T cells (CAR-T) have initially shown positive results in patients with relapsed/refractory large B-cell lymphoma, which is expected to bring new options
    to lymphoma patients.

    In the "Big Coffee Talk" session, Professor Wang Xiaopei of Peking University Cancer Hospital, Professor Qian Wenbin of the Second Affiliated Hospital of Zhejiang University, Professor Xu Wei of Jiangsu Provincial People's Hospital, Professor Shen Jianzhen of Union Hospital Affiliated to Fujian Medical University, and Professor Zhou Hui of Hunan Provincial Cancer Hospital put forward their views on "how TOCT should be positioned in today's environment of frequent lymphoma treatment measures
    ".

    With the continuous emergence of new drugs, the treatment options for lymphoma are becoming more and more individualized based on different risk stratifications, disease subtypes and other factors
    .

    At present, ASCT still occupies an important position in the treatment of lymphoma, especially in chemotherapy-sensitive patients
    .

    In addition, the relevant research to explore ASCT and new targeted drugs is also in full swing, and the "strong combination" is expected to bring more benefits
    to lymphoma patients.


    Cohesiveness, ASCT opens up a more ambitious future for leukemia treatment

    Under the auspices of Professor Xiao Zhijian of the Hospital of Hematology of the Chinese Academy of Medical Sciences, Professor Jiang Erlie of the Hematology Hospital of the Chinese Academy of Medical Sciences and Professor Zhang Yu of the Southern Hospital of Southern Medical University shared the experience and achievements
    of the Center in the design and optimization of screening and pretreatment schemes suitable for transplanted leukemia patients.

    Leukemia classification and prognosis are complex, and individualized treatment plans need to be formulated according to the patient's
    own situation.

    The screening of patients suitable for ASCT is based on molecular genetics and dynamic stratification of MRD, and FOR some patients with low- to moderate-risk leukemia, ASCT therapy can be considered after the induction therapy, consolidation intensification therapy and stem cell mobilization are all MRD-negative in the
    early stage.

    At present, the exploration of improving the efficacy of ASCT mainly focuses on optimizing induction therapy regimens to improve complete remission rates, intensive consolidation therapy to maximize MRD clearance, and adequate maintenance therapy after transplantation to reduce recurrence
    .

    There are relatively few studies on ASCT pretreatment protocols for patients with acute lymphoblastic leukemia (ALL), for which Professor Jiang Erlie's team has made some preliminary explorations
    .

    Allogeneic hematopoietic stem cell transplantation is also an important treatment for patients with acute myeloid leukemia (AML), and many domestic scholars have carried out a series of optimizations on the basis of the classical BuCy (busulfan + cyclophosphamide) pretreatment protocol, including MCBC (mefalam + cladobine + busulfan + cyclophosphamide), FBM (fludarabine + busulfan + melphalan), etc.
    , which have shown preliminary efficacy and are worth further exploration
    .

    Professor Tang Xiaowen of the First Affiliated Hospital of Soochow University, Professor Hu Jiong of Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Professor Xu Yajing of Xiangya Hospital of Central South University, Professor Wang Sanbin of the 920th Hospital of the Plaster People's Liberation Army Joint Protection Force, and Professor Qian Jiejing of the First Affiliated Hospital of Zhejiang University School of Medicine successively expressed their views and conducted in-depth discussions on whether patients with medium-risk AML CR1 need ASCT treatment.
    It is proposed that patients with a high risk of recurrence should be screened according to the risk stratification at the time of onset and the MRD status after treatment, and active interventions
    should be taken.


    The dual blessing of weapons and platforms has helped ASCT flourish

    After wonderful academic exchanges and discussions, the grand ceremony came to an end
    .

    Finally, The Chairman of the Conference, Professor Shen Zhixiang, Professor Ma Jun and Executive Chairman Professor Zou Dehui summarized the meeting, once again emphasizing that the status of ASCT in the treatment of hematological tumors is unshakable, hoping that through this meeting, more centers will be mobilized to participate in ASCT work, accumulate more experience, better screen out patients suitable for ASCT, and explore better treatment options to make more patients with hematological tumors achieve longer survival
    .

    With the application of new drugs and the optimization of transplantation technology, under the impetus of many parties, I believe that AsCT in China will become more and more vigorous!

    Edit: Arya Typesetting: Wenting Executive: Wenting

    Poke "Read the original article" to see more

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.